Introduction: Aggressive tumors of the pituitary gland are classically defined as pituitary
tumors with a massive invasion of the surrounding anatomical structures and rapid growth …

The patient was a 70-year-old man with a recurrent pituitary tumor. Three surgeries were
performed but the tumor recurred. Based on histologic, immunohistochemical and …

Purpose: A retrospective analysis of the toxicity and efficacy of temozolomide in advanced
neuroendocrine tumors. Experimental Design: Thirty-six patients with advanced stages of …

Temozolomide, an alkylating imidazol tetrazine derivative, inhibits DNA replication and is
used successfully in the management of patients with gliomas and other malignancies [5 …

Background Pituitary carcinoma (PC) is an aggressive neuroendocrine tumor diagnosed
when a pituitary adenoma (PA) becomes metastatic. PCs are typically resistant to therapy …

Interventions: The patient received the most frequently recommended regimen of
temozolomide treatment for 22 cycles. Outcomes: Temozolomide resulted in a remarkable …

Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …

The optimal treatment of pituitary carcinomas (PC) is unknown. Treatment includes surgical
resection, radiation, and more recently, temozolomide (TMZ). Pituitary adenomas have …

Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors
(APTs) and carcinomas present important diagnostic and therapeutic challenges and are …

Recent case reports have documented the efficacy of temozolomide therapy in some
aggressive pituitary adenomas and pituitary carcinomas resistant to multimodality therapy …